DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2years

AJ Hubers; DAM Heideman; S Duin; BI Witte; Harry de Koning; HJM Groen; CFM Prinsen; AS Bolijn; M Wouters; SE van der Meer; RDM Steenbergen; PJF Snijders; A Uyterlinde; H Berkhof; EF Smit; E Thunnissen

doi:10.1136/jclinpath-2016-203734

DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2years

AJ Hubers, DAM Heideman, S Duin, BI Witte, Harry de Koning, HJM Groen, CFM Prinsen, AS Bolijn, M Wouters, SE van der Meer, RDM Steenbergen, PJF Snijders, A Uyterlinde, H Berkhof, EF Smit, E Thunnissen

Public Health

Research output: Contribution to journal › Article › Academic › peer-review

19 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	250-254
Number of pages	5
Journal	Journal of Clinical Pathology
Volume	70
Issue number	3
DOIs	https://doi.org/10.1136/jclinpath-2016-203734
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/jclinpath-2016-203734

http://hdl.handle.net/1765/96669

Cite this

Hubers, AJ., Heideman, DAM., Duin, S., Witte, BI., de Koning, H., Groen, HJM., Prinsen, CFM., Bolijn, AS., Wouters, M., van der Meer, SE., Steenbergen, RDM., Snijders, PJF., Uyterlinde, A., Berkhof, H., Smit, EF., & Thunnissen, E. (2017). DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2years. Journal of Clinical Pathology, 70(3), 250-254. https://doi.org/10.1136/jclinpath-2016-203734

@article{56467fb5a54f45faa5419c7c3592c258,

title = "DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2years",

author = "AJ Hubers and DAM Heideman and S Duin and BI Witte and {de Koning}, Harry and HJM Groen and CFM Prinsen and AS Bolijn and M Wouters and {van der Meer}, SE and RDM Steenbergen and PJF Snijders and A Uyterlinde and H Berkhof and EF Smit and E Thunnissen",

year = "2017",

doi = "10.1136/jclinpath-2016-203734",

language = "Undefined/Unknown",

volume = "70",

pages = "250--254",

journal = "Journal of Clinical Pathology",

issn = "0021-9746",

publisher = "BMJ Publishing Group",

number = "3",

}

Hubers, AJ, Heideman, DAM, Duin, S, Witte, BI, de Koning, H, Groen, HJM, Prinsen, CFM, Bolijn, AS, Wouters, M, van der Meer, SE, Steenbergen, RDM, Snijders, PJF, Uyterlinde, A, Berkhof, H, Smit, EF & Thunnissen, E 2017, 'DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2years', Journal of Clinical Pathology, vol. 70, no. 3, pp. 250-254. https://doi.org/10.1136/jclinpath-2016-203734

TY - JOUR

T1 - DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2years

AU - Hubers, AJ

AU - Heideman, DAM

AU - Duin, S

AU - Witte, BI

AU - de Koning, Harry

AU - Groen, HJM

AU - Prinsen, CFM

AU - Bolijn, AS

AU - Wouters, M

AU - van der Meer, SE

AU - Steenbergen, RDM

AU - Snijders, PJF

AU - Uyterlinde, A

AU - Berkhof, H

AU - Smit, EF

AU - Thunnissen, E

PY - 2017

Y1 - 2017

U2 - 10.1136/jclinpath-2016-203734

DO - 10.1136/jclinpath-2016-203734

M3 - Article

VL - 70

SP - 250

EP - 254

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

SN - 0021-9746

IS - 3

ER -